Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame Topic

Severe recurrent anaphylaxis: investigating underlying mechanisms beyond IgE-mediated allergy - a case report.

Frontiers in allergy·2026
Same author

Adipokines in Obese Asthma: A Complex Relationship Influenced More by Sex, Weight, and Oral Steroid Treatment Than Disease Severity.

Allergy·2026
Same author

Persistent SARS-CoV-2 infection mimicking interstitial lung disease in an immunocompromised patient.

Polish archives of internal medicine·2025
Same author

Erythema nodosum followed by eosinophilic pneumonia as an adverse effect of dupilumab treatment in a patient with severe asthma.

Respiratory medicine case reports·2024
Same author

Aspirin hypersensitivity diagnostic index (AHDI): In vitro test for diagnosing of N-ERD based on urinary 15-oxo-ETE and LTE<sub>4</sub> excretion.

Allergy·2024
Same author

Machine learning in the diagnosis of asthma phenotypes during coronavirus disease 2019 pandemic.

Clinical and translational allergy·2022

Related Experiment Video

Updated: Jul 15, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

[Omalizumab in severe asthma--case report].

Agnieszka Gawlewicz-Mroczka1, Ewa Nizankowska-Mogilnicka

  • 1Klinika Pulmonologii II Katedry Chorób Wewnetrznych CM UJ w Krakowie.

Polskie Archiwum Medycyny Wewnetrznej
|April 12, 2007
PubMed
Summary

A severe asthma case in a 31-year-old woman showed poor control with standard therapy. Anti-immunoglobulin E (IgE) monoclonal antibody treatment led to significant asthma symptom improvement.

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Severe asthma management remains challenging, often requiring advanced therapeutic strategies.
  • The Global Initiative for Asthma (GINA) guidelines provide a framework for asthma control, but some patients exhibit refractory disease.
  • Immunoglobulin E (IgE) plays a crucial role in allergic inflammation and is a target for biologic therapies.

Observation:

  • A 31-year-old female patient presented with severe asthma inadequately controlled by the best available therapies as per GINA (2002) guidelines.
  • Despite adherence to established treatment protocols, the patient experienced persistent asthma symptoms and exacerbations.

Findings:

  • Administration of an anti-immunoglobulin E (IgE) monoclonal antibody resulted in a marked improvement in the patient's asthma control.

Related Experiment Videos

Last Updated: Jul 15, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

  • The patient demonstrated a significant reduction in symptom burden and likely a decrease in the frequency of asthma exacerbations post-treatment.

    • Implications:

    • This case highlights the potential efficacy of anti-IgE monoclonal antibody therapy in patients with severe, refractory asthma.
    • Biologic agents targeting IgE may represent a valuable therapeutic option for individuals failing to achieve adequate asthma control with conventional treatments.
    • Further research into personalized medicine approaches for severe asthma is warranted, considering the role of specific biomarkers like IgE.